Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
manilatimes2d
UMeWorld Transforms into a Full-Spectrum Wellness Brand with AI-Powered Personalized Solutions
UMeWorld Limited (OTC: UMEWF), renowned for its pioneering products such as DAGola Weight Loss Cooking Oil, is excited to announce its evolution into a comprehensive healthy lifestyle brand. This ...
Denali Therapeutics announces U.S. FDA BTD granted for tividenofusp
Denali Therapeutics (DNLI) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathwaySOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 ...
Denali Therapeutics initiated with an Outperform at Baird
Baird last night initiated coverage of Denali Therapeutics (DNLI) with an Outperform rating and $31 price target The firm believes Denali is ...